drugset / Trial / NCT00217841

Aurograb and Vancomycin in MRSA Infection

NCT00217841 ↗

Phase 3 Completed 180 enrolled NeuTec Pharma
RandomizedParallel-groupDouble-blindEct

Summary

The study hypothesis is that the addition of Aurograb to standard vancomycin therapy will improve outcome in MRSA infection.

Timeline

Start
2004-01
Primary completion
—
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aurograb Unknown 1 mg/kg Intravenous